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We have characterized the dopamine D2 receptor photaffinity probe, [3H]azido-iV-methylspiperone 
([3H]AMS). In the absence of light, [3H]AMS bound reversibly and with high affinity (& 70 PM) to sites 
in canine striatal membranes and was competitively inhibited by dopaminergic agonists and antagonists 
with an appropriate D2 receptor specificity. Upon photolysis, [3H]AMS covalently incorporated into a pep- 
tide of M, 92000 as assessed by fluorography following SDS-polyacrylamide gel electrophoresis. Labelling 
of this peptide was specifically and stereoselectively blocked by DZ antagonists and agonists. Minor specifi- 
cally labelled peptides of M, 70000-55000 were observed under some conditions and were the result of pro- 
teolytic degradation of the peptide at M, 92000. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Dopamine can stimulate (D1 receptors) or inhibit 
(D2 receptors) adenylate cyclase [1,2] and induce 
many psychomotor responses [3-51. A number of 
specific DZ receptor photoaffinity probes have 
been developed [6-81, but only recently has the 
ligand binding subunit of the DZ receptor been 
identified [9,10]. These photoaffinity ligands, 
however, are not commercially available. To probe 
the structure of the dopamine DZ receptor, we have 
employed a novel, high-affinity, commercially 
available, photoreactive derivative of spiperone: 
azido-N-methylspiperone [ 111. We now report here 
that (i) [3H]AMS exhibits reversible, saturable and 
stereospecific binding to striatal D2 dopamine 
receptors and (ii) upon photolysis [3H]AMS 
covalently labels a peptide of M, 92000 as the 
ligand binding subunit of the D2 receptor. 
[3H]AMS (78 Ci/mmol) was synthesized by New 
England Nuclear (Boston, MA). M, standards, 
SDS and electrophoresis reagents were obtained 
from Bio-Rad; protease inhibitors from Sigma 
[6,12,13]. 
2.1. Membrane preparation and reversible binding 
0-f ~H~AMS 
Canine striatal membranes were prepared and 
assayed for [‘H]AMS binding [6] at 22°C. Specific 
[3H]AMS binding was defined as that inhibited by 
10 pM S-sulpiride or 1 /IM (+) butaclamol. 
* To whom correspondence should be addressed 
Abbreviations: [3H]AMS, [3H]azido-iV-methylspiper- 
one; WGA, wheat-germ agglutinin 
2.2. Photoaffinity labelling and electrophoresis 
Striata were homogenized (Polytron, setting 5, 
15 s) in 50 mM Tris-HCl buffer (pH 7.4) contain- 
ing 4 mM MgC12, 120 mM NaCl in the absence or 
presence of the following protease inhibitors: 
10 mM EDTA, 15 pg/ml benzamidine, 5 pg/ml 
leupeptin, 5 pg/ml pepstatin, 5 ,ug/ml soybean 
trypsin inhibitor and 1 mM phenylmethylsulfonyl 
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fluoride at 4°C. Homogenates were centrifuged 
twice for 15 min at 48000 x g and membrane 
pellets resuspended in the above buffer. Mem- 
branes (1 mg protein/ml) were incubated in the 
dark in a total volume of 15 ml at a D2 receptor 
concentration of 300 pM with 0.8-1.0 nM 
[3H]AMS for 60 min at 22°C in the absence or 
presence of various agents and photolyzed [6]. Ir- 
radiated samples were pelleted by centrifugation 
(48000 x g; for 10 min), washed once, solubilized 
in Tris-buffer containing 1% digitonin (at 100 mg 
tissue/ml), and partially purified by WGA- 
Sepharose affinity chromatography [131. Aliquots 
(0.5 ml) of specifically eluted receptor were 
desalted over Sephadex G-50 columns at 22°C to 
exchange the buffer to 0.2% SDS, 10 mM Tris- 
HCl, pH 6.8, lyophilized overnight and brought up 
to volume with sample buffer (50 mM Tris, 10% 
SDS, 5% ,d-mercaptoethanol, 10% glycerol, 
0.005% bromophenol blue, pH 6.8). 
Aliquots (300 pg protein) were allowed to stand 
for 60 min at 22°C before being electrophoresed 
on 3 mm-thick slab gels containing 6 and 10% 
acrylamide in the stacking and separating gel, 
respectively [141. Gels used for fluorography were 
fixed, treated with Enlightning (NEN) prior to dry- 
ing using a Bio-Rad (model 224) gel dryer, and 
r 
14 A 
t 
J 
ASSOCIATION DISSOCIATION 
‘0 15 30 45 60 75 90 105 120 0 20 40 60 60 100 120 140 160 160 
TIME (min) TIME (min) 
then exposed (2-6 weeks) at -7O’C to Kodak 
XAR-5 film. Fluorographs were routinely scanned 
using a Bio-Rad scanning densitometer (model 
1650). Protein standards were visualized by 
Coomassie blue staining. Protein concentrations 
were determined as described [ 131. 
3. RESULTS AND DISCUSSION 
3.1. [3HJAMS binding to canine striatal 
preparations 
In the absence of light, the binding of [3H]AMS 
(70 PM) reached equilibrium within 120 min at 
22°C; the Kd from the on/off rates [12] was 16 pM 
(fig.1). [3H]AMS binding displayed in 120 mM 
NaCl a Kd of 59 + 4 pM and a B,, of 21 f 
2 pmol/g (fig.2). [3H]AMS binding was not 
significantly altered in the absence of NaCl (Kd 77 
f 8 PM; &ax 21 + 1 pmol/g) or in the presence of 
multiple protease inhibitors (Kd 56 + 6 pM; B,,,, 
22 + 1 pmol/g). The specific binding of [3H]AMS 
accounted for 70-80% of total binding. 
Dopaminergic compounds specifically inhibited 
the binding of [3H]AMS (70 PM) (fig.3). 
Agonist/[3H]AMS competition curves had a Hill 
slope less than one and were best described by 
computer-assisted analysis [ 151 as comprising two 
Fig. 1. Kinetics of [3H]AMS binding to striatal membranes. For association experiments (A), membranes were incubated 
in the dark with [“HIAMS (70 PM) for various time periods and assayed for DZ receptor activity. The association rate 
constant for [3H]AMS was determined to be 4.167 x 10m4 PM-’ amin-‘. (B) Dissociation of [3H]AMS: following 
equilibrium, dissociation was initiated by the addition of 500 nM YM-09151-2, and the dissociation rate constant 
determined to be 0.006456 min-‘. 
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Fig.2. Saturation isotherm of [‘H]AMS binding to 
canine striatal membranes. Striatal homogenates were 
incubated in the dark with increasing concentrations of 
i3H]AMS (10-1000 PM) for 120 min at 22°C and 
assayed for Dz dopamine receptor activity. The data 
were analyzed by the non-linear least-squares computer 
program LIGAND. Each point is the mean obtained 
from triplicate determinations and is representative of 
three independent experiments. B,,, and & values for 
[3H]AMS binding are listed in the text. Inset: Structure 
of [3H]AMS. 
sites (table 1 where Dpgh and Dp” represent 
agonist high- ind low-affinity forms of the recep- 
tor). The competitive binding of [3H]AMS to 
canine striatal membranes was virtually identical 
to that of the parent probe, [3H]spiperone [12]. 
3.2. Covalent photoincorporation of cH]AMS 
into Dz-receptors 
In membrane preparations [3H]AMS labelled in 
a photo-dependent and specific manner a peptide 
of M, 90000-94000, as assessed by liquid scintilla- 
tion counting of gel slices following elec- 
trophoresis. However, the low amount of label 
incorporated into this peptide (100-300 cpm) 
precluded the fluorographic visualization of the 
receptor despite exposure times of up to six weeks. 
We chose to enrich [3H]AMS-photolabelled mem- 
brane receptors by WGA-Sepharose affinity 
chromatography ]16-181 (fig.4). Under these con- 
ditions [‘H]AMS incorporated covalently into a 
major protected band at M, 92000. Moreover, one 
to two minor bands appear at it4, 70000-59000 
that were protected by dopaminergic antagonists 
and the agonist (fig.4B) N-propylnorapomorphine 
(- NPA). The Dz dopaminergic nature of these 
labelled peptides was also shown by the fact that 
Fig.3. Ability of dopaminergic agonists (A) and 
antagonists (B) to compete for [3H]AMS binding to 
striatal membranes. Increasing concentrations of 
dopaminergic agonists and antagonists were incubated 
in the dark with 70 pM [3H]AMS and assayed for Dz 
receptor activity. Data were analyzed for one and two 
site fits by the non-linear least-squares computer 
program LIGAND. The results shown here are the 
means of triplicate determinations and are representative 
of three independent experiments. 
1 gM ketanserin, a serotonergic SZ receptor an- 
tagonist only slightly attenuated [3H]AMS photo- 
incorporation. Neither SCH-23390 (1 PM), a 
dopamine Di receptor antagonist, nor the /3- 
adrenergic receptor antagonist propranolol 
(10 PM), afforded any protection against 
[3H]AMS photo-incorporation (not shown). Con- 
trol experiments revealed that under non- 
photolysing conditions [‘H]AMS did not covalent- 
ly incorporate into any peptide, and that radioac- 
tivity associated with the 92 kDa peptide could not 
be extracted by chloroform: methanol (3 : l), in- 
dicating that it is a protein. Pre-exposure of 
[3H]AMS to UV light did not affect its ability to 
bind to DZ receptors in a reversible and saturable 
manner with high affinity (70 PM), satisfying most 
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Table 1 
Agonist and antagonist dissociation constants for the Dz dopamine receptor 
December 1986 
Agonist & (nM) Proportion (Yo) 
Dij&h low 
D2 
D:“h low 
D2 
Antagonist 
( - )NPA 3 539 
( + )ADTN 16 532 
Dopamine 61 4047 
( + )NPA 82 1428 
Noradrenaline 241 19840 
Serotonin 2292 37310 
87 13 spiperone 0.050 
52 48 (+)butaclamol 1.1 
49 51 ( - )sulpiride 14.4 
27 73 ketanserin 674 
38 62 SCH-23390 857 
49 51 ( - )butaclamol 8438 
Canine striatal membranes were prepared and assayed for Dz receptor activity as 
described in section 2. All data were analyzed by the computer program LIGAND for 
one and two site fits. Values represent he means of 3 independent determinations with 
a SE of <15%. NPA, lO,ll-hydroxy-N-propylnorapomorphine; ADTN, 
6,7-dihydroxy-2-aminotetralin 
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Fig.4. Photoaffinity labelling and pharmacological specificity of 13H]AMS incorporation into canine striatal 
membranes. Striatal homogenates were incubated with [‘H]AMS (800-1000 PM) alone or with (A) antagonists or (B) 
N-propylnorapomorphine (- NPA), photolyzed, solubilized, applied to WGA-Sepharose and finally electrophoresed on 
10% gels as described in section 2. The results shown are identical with two other experiments. Arrows represent he 
ikf, of some known protein standards and shown x 1000 (K). SPIP, spiperone; BTC, butaclamol; SULP, sulpiride; 
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Fig.5. Effect of protease inhibitors on the photoaffinity 
labelling pattern of [3H]AMS into canine striatal 
membranes. Striatal membranes were prepared either in 
the absence or presence of 10 mM EDTA, 5 ,ug/ml 
soybean trypsin inhibitor, 5 pg/ml leupeptin, 5 fig/ml 
pepstatin, 15 pg/ml benzamidine, 1mM 
phenylmethylsulfonyl fluoride. Membranes were 
incubated with [3H]AMS (1000 PM) alone and in the 
presence of 1 pM (+)-butaclamol, and processed for 
electrophoresis a described in section 2. Abbreviations 
used are as described in fig.4. 
of the requirements of a photoaffinity label. The 
protein labelled by [‘H]AMS as the ligand binding 
subunit of the DZ dopamine receptor (Mr 92000) 
corresponds to that recently reported [9,10,19]. 
Failure to inhibit endogenous proteinase activity 
during photoaffinity labelling may allow for the 
generation of peptide fragments which retain the 
pharmacological specificity of native receptors 
[20]. As seen in fig.5, photolabelling brain mem- 
brane receptors in the absence of protease in- 
hibitors allows for the generation of multiple 
specifically labelled fragments with M, values of 
92000, 70000,60000 and 55000. Photolabelling in 
the presence of multiple protease inhibitors, 
however, resulted in the labelling of a single major 
peptide of M, 92000 while greatly attenuating the 
labelling of lower molecular-mass fragments. We 
conclude, therefore, that all specifically labelled 
peptides seen in fig.4A and B are probably the 
result of proteolytic degradation of the peptide at 
M, 92000. The metalloprotease inhibitor, EDTA 
(10 mM), did not appear to prevent he appearance 
of multiple labelled peptides of M, 70000-55000 
(not shown). 
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